Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond

被引：423

作者：

Ghofrani, Hossein A.

Osterloh, Ian H.

Grimminger, Friedrich

机构：

[1] Univ Hosp Giessen & Marburg GmbH, Dept Internal Med, Med Clin 2 5, D-35392 Giessen, Germany

[2] Pfizer Ltd, Sandwich CT13 9NJ, Kent, England

来源：

NATURE REVIEWS DRUG DISCOVERY | 2006年 / 5卷 / 08期

关键词：

D O I：

10.1038/nrd2030

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

In less than 20 years, the first selective type 5 phosphodiesterase inhibitor, sildenafil, has evolved from a potential anti-angina drug to an on-demand oral treatment for erectile dysfunction ( Viagra), and more recently to a new orally active treatment for pulmonary hypertension (Revatio). Here we describe the key milestones in the development of sildenafil for these diverse medical conditions, discuss the advances in science and clinical medicine that have accompanied this journey and consider possible future indications for this versatile drug.

引用

收藏

页码：689 / 702

页数：14

相关论文

共 201 条

[51] Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity [J].

Fisher, PW ;

Salloum, F ;

Das, A ;

Hyder, H ;

Kukreja, RC .

CIRCULATION, 2005, 111 (13) :1601-1610

[52] A double blind, randomised study of sildenafil citrate for erectile dysfunction in men with multiple sclerosis [J].

Fowler, CJ ;

Miller, JR ;

Sharief, MK ;

Hussain, IF ;

Stecher, VJ ;

Sweeney, M .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2005, 76 (05) :700-705

[53] Sildenafil citrate does not reduce exercise tolerance in men with erectile dysfunction and chronic stable angina [J].

Fox, KM ;

Thadani, L ;

Ma, PTS ;

Nash, SD ;

Keating, Z ;

Czorniak, MA ;

Gillies, H ;

Keltai, M .

EUROPEAN HEART JOURNAL, 2003, 24 (24) :2206-2212

[54]

Francis SH, 2001, PROG NUCLEIC ACID RE, V65, P1

[55] Ligand-induced conformational changes in cyclic nucleotide phosphodiesterases and cyclic nucleotide-dependent protein kinases [J].

Francis, SH ;

Chu, DM ;

Thomas, MK ;

Beasley, A ;

Grimes, K ;

Busch, JL ;

Turko, IV ;

Haik, TL ;

Corbin, JD .

METHODS, 1998, 14 (01) :81-92

[56] Nonarteritic anterior ischemic optic neuropathy and sildenafil [J].

Fraunfelder, FW ;

Pomeranz, HD ;

Egan, RA .

ARCHIVES OF OPHTHALMOLOGY, 2006, 124 (05) :733-734

[57] Sildenafil improves quality of life in men with heart failure and erectile dysfunction [J].

Freitas, D ;

Athanazio, R ;

Almeida, D ;

Dantas, N ;

Reis, F .

INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2006, 18 (02) :210-212

[58] Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy [J].

Fries, R ;

Shariat, K ;

von Wilmowsky, H ;

Böhm, M .

CIRCULATION, 2005, 112 (19) :2980-2985

[59] Emereing medical therapies for pulmonary arterial hypertension [J].

Galiè, N ;

Manes, A ;

Branzi, A .

PROGRESS IN CARDIOVASCULAR DISEASES, 2002, 45 (03) :213-224

[60] Sildenafil citrate therapy for pulmonary arterial hypertension [J].

Galiè, N ;

Ghofrani, HA ;

Torbicki, A ;

Barst, RJ ;

Rubin, LJ ;

Badesch, D ;

Fleming, T ;

Parpia, T ;

Burgess, G ;

Branzi, A ;

Grimminger, F ;

Kurzyna, M ;

Simonneau, G .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (20) :2148-2157

← 1 2 3 4 5 6 7 8 9 10 →